It is well known that a high proportion of patients with compensated cirrhosis (Child-Pugh A) remain so far many years. Once clinical decompensation has occoured, the prognosis is very poor. There is growing evidence that the use of Interferon (IFN) as a therapy for chronic hepatitis C may slaken the natural history of the pathology. The use of IFN in viral cirrhosis is controversial with respect to its effectiveness. We conducted a trial with IFN (59 patients, average age: 55.3 ± 7) vs no therapy (71 patients, average age: 56.8 ± 8) in HCV compensated cirrhosis with abnormal ALT and HCV-RNA positive serum to investigate the incidence of negative events: clinical-laboratoristic worsening (Child B or C, death, orthotopic liver transplantation) or hepatocellular carcinoma (HCC) (mean follow-up 96 ± 18.3 months). In the treated patients the negative events altogether evaluated were present in 45% of cases, in non treated patients in 88.7%. In particular, in the non-treated group the cases with clinical-laboratoristic worsening are higher even as regards the treated ones, independently from the type of response. IFN therapy does not reduce the risk of HCC. It can be concluded that the therapy with IFN can be effective in reducing the possibility of the passage from Child A to Child B or C, of death and of liver transplantation.
|Translated title of the contribution||HCV compensated cirrhosis: Role of interferon therapy|
|Number of pages||5|
|Publication status||Published - Dec 2002|
ASJC Scopus subject areas
- Internal Medicine